- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03500328
Traditionelle vs. frühe aggressive Therapie für Multiple Sklerose-Studie (TREAT-MS)
Eine pragmatische Studie zur Bewertung der mittelfristigen Auswirkungen einer frühen, aggressiven gegenüber einer Eskalationstherapie bei Menschen mit Multipler Sklerose
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.
The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Sonstiges: Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
- Sonstiges: Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
Detaillierte Beschreibung
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.
The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.
Hypotheses/Objectives: The main hypothesis is that intermediate-term disability will be reduced by earlier use of higher-efficacy medications. Additional objectives include a) evaluating the magnitude of the treatment effect in patients deemed to be at higher risk versus lower risk of longer-term disability (we hypothesize that the effect size will be greater in the former group) and b) evaluating if, among those without indications of a high risk of longer-term disability, breakthrough disease can be successfully managed by switching to a different first-line therapy or if escalation is required at that time (we hypothesize that switching to a higher-efficacy therapy will be more effective in preventing disability in this group).
There is a great unmet need to identify the most appropriate treatment strategy for people with MS, especially early in the disease course when it may be possible to maximize an individual's chance for preventing long-term disability. There is a paucity of evidence-based guidelines to help clinicians, patients, and payers determine which treatment strategy is best for an individual with MS. Making treatment decisions is a daunting task, and the individualized benefit-risk assessment becomes increasingly difficult as new therapies emerge. Without the availability of direct comparative trials, clinicians and patients are forced to scrutinize observational studies that only provide basic insights into what may be the best treatment path moving forward. It is equally challenging to define what constitutes a suboptimal response to a DMT for an individual patient. Clinicians lack guidance on when to switch therapies and whether to consider a different first-line or if clinicians should escalate immediately to higher-efficacy therapies, so further consensus is needed to determine the optimal time to switch therapies and escalate therapy if an individual is on a first-line therapy from the start. The TREAT-MS trial will help inform patients and the broader health care community on whether patients would most benefit from early, possibly more risky aggressive therapy or if starting with a less aggressive (and, often, less risky) therapy, followed by a switch if breakthrough disease occurs, is warranted. In addition, this study may help identify specific patient populations and/or short-term clinical and paraclinical biomarkers that are strongly predictive of long-term disability that can ensue from MS.
Accrual of sustained disability is the most feared complication for people with MS, and the patient's own perception of their well-being or ill-being has a profound impact on their quality of life. The heterogeneity and unpredictability of MS, along with lack of agreed upon treatment guidelines, augments this fear, leading to a significant negative impact on quality of life. Even patients who are deemed to have "mild" MS experience a significant negative impact on their health-related quality of life that is similar in magnitude to what patients with other severe chronic conditions (i.e., congestive heart failure and chronic obstructive pulmonary disease) report. An extremely important goal for any intervention is to help improve or maintain a high quality of life; therefore, in addition to classic clinical endpoints (e.g. slowing disability progression), the TREAT-MS trial will capture several important and meaningful PROs that will shed light on what treatment strategies may be the best from a patient-centered perspective.
COVID-19 Related Substudy:
Since early 2020, the coronavirus disease 2019 (COVID-19) pandemic has caused clinical care and research disruptions nationwide, including for patients enrolled in the TREAT-MS trial. Many patients with MS, as well as their clinicians, are fearful that MS or the MS therapy they are using may increase the risk or severity of COVID-19 infection. Whether a person with early MS is more likely to experience more severe COVID-19 if treated with a higher-efficacy therapy is not known. Further, whether COVID-19-induced disruptions in therapy or other clinical care increase MS disease activity or MS symptoms is not clear but is relevant, particularly since greater MS activity in the early therapeutic course is associated in observational studies with worse long-term outcomes. Moreover, it is unclear if pre-pandemic anxiety and depression, common comorbidities in people with MS, contribute to decisions to delay care, overall or differently depending on therapeutic strategy (higher-efficacy vs. traditional). TREAT-MS provides an optimal cohort in which to investigate the effect of the COVID-19 pandemic on MS outcomes.
COVID-19 Substudy Aim 1. To evaluate if patients enrolled in TREAT-MS delayed or altered their disease-modifying therapy schedule or other MS care, and whether such alterations are associated with a greater degree of breakthrough inflammatory disease activity or the development of new (or worsening baseline) MS symptoms.
COVID-19 Substudy Aim 2: To evaluate if patients with MS treated with higher-efficacy, versus traditional, therapies differ in the risk of severe COVID-19 infection, defined as requiring hospitalization (with or without intubation) or mortality due to COVID-19.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- University of Alabama at Birmingham
-
Mobile, Alabama, Vereinigte Staaten, 36604
- The University of South Alabama
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85013
- St. Joseph's Hospital & Medical Center - Barrow Neurological Institute
-
-
California
-
Carmichael, California, Vereinigte Staaten, 95608
- CommonSpirit Health Research Institute
-
Los Angeles, California, Vereinigte Staaten, 90095
- University of California, Los Angeles
-
Los Angeles, California, Vereinigte Staaten, 90048
- Cedars-Sinai Medical Center
-
San Diego, California, Vereinigte Staaten, 92037
- University of California, San Diego
-
San Francisco, California, Vereinigte Staaten, 94158
- University of California, San Francisco
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Christiana Care Health Services, Inc.
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20007
- Georgetown University
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32611
- University of Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami
-
Tampa, Florida, Vereinigte Staaten, 33612
- University of South Florida Health
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rush University Medical Center
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- The University of Kansas Medical Center (KUMC)
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40207
- Norton Neurology MS Services
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- The Johns Hopkins Hospital
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland, Baltimore
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- University of Massachusetts Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic
-
-
Montana
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Advanced Neurology Specialists
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- University of Nebraska Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University Medical Center
-
New York, New York, Vereinigte Staaten, 10016
- New York University School of Medicine
-
New York, New York, Vereinigte Staaten, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- University of Cincinnati
-
Columbus, Ohio, Vereinigte Staaten, 43214
- OhioHealth Research Institute
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Oklahoma Medical Research Foundation
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97225
- Providence Health and Services - Oregon
-
-
Pennsylvania
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Geisinger Clinic
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny Health Network Research Institute
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37215
- Vanderbilt Comprehensive MS Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75246
- Baylor Scott and White Health
-
Dallas, Texas, Vereinigte Staaten, 75390-8806
- University of Texas Southwestern Medical Center
-
Round Rock, Texas, Vereinigte Staaten, 78681
- Central Texas Neurology Consultants
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84108
- University of Utah
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05405
- The University of Vermont and State Agricultural College
-
-
Virginia
-
Christiansburg, Virginia, Vereinigte Staaten, 24073
- Blacksburg Neurology
-
Norfolk, Virginia, Vereinigte Staaten, 23502
- Neurology Consultants of Tidewater
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98122
- Swedish Health Services
-
Seattle, Washington, Vereinigte Staaten, 98133
- University of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged 18-60 years
- Meets 2017 McDonald criteria for relapsing-remitting MS [patients with clinically isolated syndrome (CIS) are not eligible]
- Must be EITHER John Cunningham (JC) virus antibody negative or low positive (index antibody titer <0.9), OR negative for: Hepatitis B and C, tuberculosis
- HIV negative
- No chemotherapy in past year; if patient has prior history of chemotherapy or malignancy, documentation in chart explaining why potential risks of higher-efficacy therapy are justified
Exclusion Criteria:
- Prior treatment with rituximab, ocrelizumab, ofatumumab, alemtuzumab, mitoxantrone or cladribine
- Prior treatment with any other MS DMT for more than 6 months
- Prior treatment with experimental aggressive therapies (e.g., T-cell vaccine, total lymphoid radiation, stem cells)
- Treatment with teriflunomide within past 2 years (even for ≤ 6 months), unless rapid wash out done (i.e., with cholestyramine or activated charcoal)
- Treatment in the past 6 months with any MS DMT
- Prior treatment with any other investigational immune-modulating /suppressing drug for MS not listed above
- Pregnant or breast-feeding
- Women of child-bearing age who are planning or strongly considering conception during the study time frame
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Early Aggressive Therapy
Early Aggressive Therapy choices and maximum allowable doses:
|
Early Aggressive Therapy
Andere Namen:
|
|
Aktiver Komparator: Traditional Therapy
Traditional Therapy choices and maximum allowable doses:
|
Traditional Therapy
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to sustained disability progression
Zeitfenster: From date of randomization until the date of first documented sustained disability progression, up to 99 months
|
Time to sustained disability progression is measured by the Expanded Disability Status Scale plus (EDSS+): a composite endpoint that includes EDSS change (change at any 6 month time point of > or = 1.0 point if baseline EDSS is < or = 5.5 or of > or = 0.5 if baseline EDSS is > or = 6.0, that is sustained 6 months later) OR 20% worsening on either of two specific components of the Multiple Sclerosis Functional Composite (MSFC), the timed 25-foot walk test (T25FWT) and the nine hole peg test (9HPT) that is sustained 6 months later. |
From date of randomization until the date of first documented sustained disability progression, up to 99 months
|
|
Change in Overall Burden of MS
Zeitfenster: up to 48 weeks from enrollment into COVID-19 related substudy
|
The change in overall burden of MS will be defined for the COVID-19 related substudy as the occurrence of breakthrough disease (relapses or new MRI activity) or the development of new (or worsening baseline) MS symptoms, which are (for TREAT-MS) and will continue to be (during the substudy) documented at clinical visits, whether in-person or on tele-visits. |
up to 48 weeks from enrollment into COVID-19 related substudy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient-Determined Disease Steps (PDDS)
Zeitfenster: up to 99 months
|
PDDS is a self-assessment scale of disability due to MS on a scale from 0 to 8 and will be administered as an electronic patient-reported outcome (PRO). |
up to 99 months
|
|
Multiple Sclerosis Functional Composite (MSFC) Composite Score
Zeitfenster: up to 99 months
|
The MSFC consists of the timed 25 foot walk test, the 9-hole peg test, and the Paced Auditory Serial Addition Test (PASAT) and a composite MSFC z-score will be evaluated. |
up to 99 months
|
|
Timed 25 Foot Walk Test
Zeitfenster: up to 99 months
|
Time taken to complete the timed 25 foot walk test, measured twice in units of seconds, will be averaged and evaluated. |
up to 99 months
|
|
Nine-hole Peg Test
Zeitfenster: up to 99 months
|
Time taken to complete the nine-hole peg test, measured twice for each hand (dominant and non-dominant) in units of seconds, will be averaged for each hand and evaluated. |
up to 99 months
|
|
Paced Auditory Serial Addition Test (PASAT)
Zeitfenster: up to 99 months
|
The paced auditory serial addition test that measures processing speed will be administered once; number and percent correct will be evaluated. |
up to 99 months
|
|
Low contrast visual acuity
Zeitfenster: up to 99 months
|
Low-contrast letter acuity (binocular, 2.5% contrast Sloan charts) |
up to 99 months
|
|
Patient-reported incomplete relapse recovery
Zeitfenster: up to 99 months
|
Among participants identified to have a relapse, relapse recovery will be defined as complete or incomplete based on patient self-report. |
up to 99 months
|
|
Neurologic exam-based incomplete relapse recovery
Zeitfenster: up to 99 months
|
Among participants identified to have a relapse, relapse recovery will be defined as complete or incomplete based on neurologic examination (those who have increased Functional System scores, corresponding to the relapse symptoms, of 1.0 point or greater for at least 6 months after the relapse onset, without subsequent accrual of worsening in that same Functional System (e.g. more indicative of progression), will be considered to have incomplete relapse recovery). |
up to 99 months
|
|
Cognition using Symbol Digit Modality Test (SDMT)
Zeitfenster: up to 99 months
|
The SDMT is commonly used in MS to assess processing speed and will be administered orally and used to evaluate changes in cognition throughout the study. |
up to 99 months
|
|
Multiple Sclerosis Impact Scale (MSIS-29)
Zeitfenster: up to 99 months
|
The MSIS-29 will be used to evaluate the impact of MS on the participants and will be administered as an electronic PRO.Multiple Sclerosis Impact Scale (MSIS-29) is an instrument used for measuring the physical (20 items) and psychological (nine items) impact of multiple sclerosis. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Anxiety Subscale
Zeitfenster: up to 99 months
|
The Anxiety Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Depression Subscale
Zeitfenster: up to 99 months
|
The Depression Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Fatigue Subscale
Zeitfenster: up to 99 months
|
The Fatigue Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Upper Extremity Function
Zeitfenster: up to 99 months
|
The Upper Extremity Function Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Lower Extremity Function
Zeitfenster: up to 99 months
|
The Lower Extremity Function Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Cognitive Function
Zeitfenster: up to 99 months
|
The Cognitive Function Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Positive Affect/Well-being
Zeitfenster: up to 99 months
|
The Positive Affect/Well-being Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Sleep Disturbance
Zeitfenster: up to 99 months
|
The Sleep Disturbance Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Ability to Participate in Social Roles and Activities
Zeitfenster: up to 99 months
|
The Ability to Participate in Social Roles and Activities Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Satisfaction with Social Roles and Activities
Zeitfenster: up to 99 months
|
The Satisfaction with Social Roles and Activities Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Quality of Life in Neurological Disorders (Neuro-QoL): Stigma
Zeitfenster: up to 99 months
|
The Stigma Subscale of Neuro-QoL will be administered as an electronic PRO. |
up to 99 months
|
|
Employment status
Zeitfenster: up to 99 months
|
The incidence of change in employment to "disabled" or "looking for work, unemployed," will be evaluated for all participants through an electronic PRO. |
up to 99 months
|
|
Marital status
Zeitfenster: up to 99 months
|
Incident divorce or separation, among those who previously were married or in a domestic partnership, will be evaluated for all participants through an electronic PRO. |
up to 99 months
|
|
Serious Adverse Events (SAEs)
Zeitfenster: up to 99 months
|
SAEs (clinically significant infections, malignancies, or the development of other serious comorbidities, as well as unplanned hospitalizations [for non-elective issues, excluding MS relapse] and death) |
up to 99 months
|
|
Adverse event resulting in a decision to change disease-modifying therapy
Zeitfenster: up to 99 months
|
Adverse events meaningful enough to lead to medication discontinuation |
up to 99 months
|
|
Severe COVID-19 Infection
Zeitfenster: up to 48 weeks from enrollment into COVID-19 related substudy
|
Severe COVID-19 infection will be defined as an outcome of "hospitalization or death" due to confirmed or suspected COVID-19 infection |
up to 48 weeks from enrollment into COVID-19 related substudy
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Ellen M. Mowry, MD, MCR, Johns Hopkins University
- Hauptermittler: Scott D. Newsome, DO, Johns Hopkins University
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Demyelinisierende Autoimmunerkrankungen, ZNS
- Autoimmunerkrankungen des Nervensystems
- Demyelinisierende Krankheiten
- Multiple Sklerose
- Multiple Sklerose, schubförmig remittierend
- Peptide
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Therapeutika
- Routen der Arzneimittelverwaltung
- Arzneimitteltherapie
- Nukleinsäuren, Nukleotide und Nukleoside
- Biologische Faktoren
- Säuren, acyclisch
- Carboxylsäuren
- Amine
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Purines
- Alkohole
- Glykole
- Membranproteine
- Nukleoside
- Ribonukleoside
- Interzelluläre Signalpeptide und Proteine
- Aminoalkohole
- Sphingosin
- Propylenglykole
- Antikörper, monoklonale, murine abgeleitete
- Desoxyribonukleoside
- Zytokine
- Interferon Typ i
- 2-Chloroadenosin
- Adenosin
- Purin -Nukleoside
- Desoxyadenosinen
- Injektionen
- Dicarboxylsäuren
- Vesikuläre Transportproteine
- Interferon-Beta
- Interferon beta-1a
- Rituximab
- Natalizumab
- Fingolimod-Hydrochlorid
- Interferon beta-1b
- Alemtuzumab
- Glatirameracetat
- Dimethylfumarat
- Interferone
- Cladribin
- Ozanimod
- Teriflunomid
- Ocrelizumab
- Ofatumumab
- Injektionen, subkutan
- Peginterferon Beta-1a
- Siponimod
- Diroximel Fumarat
- Monomethylfumarat
- Ponesimod
- Injektionen, intramuskulär
- Fumarate
- Mantelproteinkomplex I
Andere Studien-ID-Nummern
- IRB00143534
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .